Although PD -1 or CTLA-4 monoclonal antibody may show some efficacy in colorectal cancer with DNA mismatch repair deficiency, more accurate biomarkers to predict immunotherapy effect remain to be found. Here, RPL17 is linked to colorectal cancer.